budeson 3 mg capsules
rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.
budesonide/kleva nasal spray suspension 2mg/ml
kleva s.a. 189 parnithos avenue, 13671 acharnai, attiki, greece - budesonide - nasal spray, suspension - budesonide 100 µg - nasal preparations
entocort enema 2.3 mg rect. susp. (tabl.)
tillotts pharma gmbh - budesonide, micronised 2,3 mg/ml - tablet for rectal suspension - 2,3 mg - budesonide 2.3 mg - budesonide
budesonide teva 0.5mg / 2 ml nebuliser suspension
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - budesonide - nebuliser suspension - budesonide 0.25 mg/ml - drugs for obstructive airway diseases
budenofalk 3 mg hard caps.
dr. falk pharma benelux b.v. - budesonide 3 mg - capsule, hard - 3 mg - budesonide 3 mg - budesonide
budesonide capsule, delayed release
bryant ranch prepack - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide delayed-release capsules are indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. budesonide delayed-release capsules are indicated for the maintenance of clinical remission of mild to moderate crohn’s disease involving the ileum and/or the ascending colon for up to 3 months in adults. budesonide delayed-release capsules are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide delayed-release capsules. serious hypersensitivity reactions, including anaphylaxis have occurred [see adverse reactions (6.2)] . risk summary limited published studies report on the use of budesonide in pregnant women; however, the data are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are clinical considerations [see clinical considerations] . in animal reproduction studies with pregnant rats and rabbits, administration of
budesonide teva pharma 1 mg/2 ml nebuliser suspension
teva pharma b.v. - budesonide - nebuliser suspension - 1 mg/2ml - glucocorticoids; budesonide
budesonide teva pharma 0.5 mg/2 ml nebuliser suspension
teva pharma b.v. - budesonide - nebuliser suspension - 0.5 mg/2ml - glucocorticoids; budesonide
entocort ec- budesonide capsule
prometheus laboratories inc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - entocort ec is indicated for - the treatment of mild to moderate active crohn's disease involving the iluem and/or the ascending colon and - the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months. the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months. entocort ec is contraindicated in patients with known hypersensitivity to budesonide.
budesonide spray metered
astrazeneca pharmaceuticals lp - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 32 ug